Previous 10 | Next 10 |
The race is on for a vaccine for the coronavirus. Over the last 24 hours, up to 9,000 have been infected with the virus just in the U.S. Up to 149 have now died. Worse, according to the U.S. government, the pandemic could last 18 months or longer, and “include multiple waves of illness...
Trillium Therapeutics (NASDAQ: TRIL ): FY GAAP EPS of -$1.65 misses by $0.43 . More news on: Trillium Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Trillium Therapeutics (NASDAQ: TRIL ) has resumed trading from a halt and is up 66.1% on the day - down from a session peak when it was up 93% . More news on: Trillium Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: iBio (NYSEMKT: IBIO ) +181% . More news on: iBio, Inc., Dynatronics Corporation, Altimmune, Inc., Stocks on the move, , Read more ...
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. ( the “Company”) (NASDAQ/TSX: TRIL) wishes to confirm that it is not aware of any material, undisclosed informat...
Dynatronics (NASDAQ: DYNT ) +224% . More news on: Dynatronics Corporation, Altimmune, Inc., Allied Healthcare Products, Inc., Stocks on the move, , Read more ...
Gilead Sciences (NASDAQ: GILD) is reportedly in buyout, or possible licensing, talks with the clinical-stage cancer company Forty Seven (NASDAQ: FTSV) , according to Bloomberg. Forty Seven's lead drug candidate, magrolimab , targets a fairly unique therapeutic pathway named CD47. By inhi...
Trillium Therapeutics ( TRIL ) is a biotech that should be on everyone's radar. There are several reasons to be highlighted below, but one main reason is because the mechanism of action of targeting CD47 has been proven by a peer. This target involves the next generation of checkpoint inhibi...
Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company devel...
With another choppy market session in the books, investors remain focused on small-cap stocks. Also known as penny stocks , these low-priced equities tend to perform well during times of both market uncertainty and stagnation. This time around we might be seeing both. During the last 6 sessions...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...